Nouveaux agents Nouvelles destinations Fair-Embolisation et agents - - PowerPoint PPT Presentation

nouveaux agents nouvelles destinations
SMART_READER_LITE
LIVE PREVIEW

Nouveaux agents Nouvelles destinations Fair-Embolisation et agents - - PowerPoint PPT Presentation

Nouveaux agents Nouvelles destinations Fair-Embolisation et agents liquides Vincent VIDAL Nouveaux liquides Onyx, Squid, Phil, Easyx and others Transcatheter embolization in animal models with GPX, a novel water-borne polymer embolic.


slide-1
SLIDE 1

Nouveaux agents Nouvelles destinations

Fair-Embolisation et agents liquides

Vincent VIDAL

slide-2
SLIDE 2

Nouveaux liquides

Transcatheter embolization in animal models with GPX, a novel water-borne polymer embolic.

Joshua P. Jones, PhD; Jessica C. Karz; and Matthew S. Johnson, MD, FSIR

Swine Kidney and Liver Embolizations

  • All procedures/evaluations were done by non-Fluidx personnel.
  • A Boston Scientific Direxion HI-FLO microcatheter (0.027” ID)

was placed proximal to the target vasculature.

  • GPX was injected (~0.3 mL) over 1 min. Embozene Microspheres

(40µm) were used as a control (deployed as per the IFU).

  • Occlusion was assessed at 15 m and 14 d (see Table 1).

Diverse Use Scenarios

  • GPX was deployed into coils at multiple sites including the rete

mirabile as well as the splenic, gastric, and renal arteries.

  • In rabbits, elastase was used to create model aneurysms in the

subclavian artery. Embolization was performed using a balloon and jailed catheter technique. Follow-up was performed at 28 d.

  • These procedures explored the use of GPX with a variety of

catheters ranging from 0.017” ID (Medtronic Echelon 10) to 0.041” ID (Terumo Glidecath).

GPX (Fluidx Medical Technology, Salt Lake City, UT) is a new type of transcatheter embolic: a water-based coacervate which solidifies upon injection into the

  • vasculature. The agent is primarily comprised of two
  • ppositely

charged polymers, with interactions shielded by high concentrations of monovalent ions (salt). Tantalum powder is added for radiopacity. Solidification results from strengthened interactions between the

  • ppositely

charged polymers in response to decreasing salt concentration (Figure 1). This produces a cohesive viscoelastic gel that can be delivered with control and precision without adhering to catheters. Here, the performance of the GPX embolic was evaluated in procedures out to 14 days in a porcine model and 1 month in a rabbit model. GPX was used alone and in combination with other agents to simulate a variety of clinical scenarios.

Purpose Materials & Methods Results Conclusions

AFA Flow Scale Grade Definition AFA Grade No antegrade flow within the treatment site. AFA Grade 1 Contrast passes into the treatment site but “hangs up” and fails to opacify the entire distal vascular bed. AFA Grade 2 Antegrade filling of contrast with complete filling of the artery and its major and minor branches after more than two cardiac cycles. Alternatively, delayed contrast washout in the target site territory may occur , compared with comparable areas of distal vascular bed not perfused by the target site. AFA Grade 3 Antegrade flow of contrast with complete filling of the vessel and its major and minor branches within two cardiac cycles. Contrast also clears from the arterial segment within two cardiac cycles.

Post Injection (0.9% Saline) Coacervate (6-9% Saline) Figure 1: GPX solidifies after delivery in response to decreasing salt concentration. Table 1: The AFA Flow Scale was used to grade

  • cclusion at 15 minutes and 14 days.

Swine Kidney and Liver Embolization

  • GPX distally penetrated into small arteries

without fragmentation, resulting in immediate occlusion.

  • All treatment sites [n=20] showed no flow

(AFA grade 0) at the acute follow-up, compared with an average of 0.7 (+/-0.6) for microspheres [n=4].

  • In the survival arm, all sites remained fully
  • ccluded

(AFA=0) at 14 days [n=7]. Microspheres had an average AFA score of 2.3 (+/- 1.2) [n=4].

  • At necropsy, GPX remained cohesive and

was well distributed in the target tissue. Penetration was seen into small arterioles.

Initial angiogram 15 minutes post 14 days post Faxitron of GPX GPX placement

Figure 2: Porcine kidney embolization using GPX at 14 days.

Initial angiogram Coil placement Minimal
  • cclusion
With GPX: total
  • cclusion
Necropsy minutes post-injection: GPX did not fragment and displayed distal penetration

Figure 3: Diverse uses of

  • GPX. Top: With coil. Right:

Acute necropsy. Bottom: Swine rete mirabile (left) and aneurysm model (right).

Initial angiogram GPX embolization No balloon adhesion after embolization of rabbit aneurysm

Diverse Use Scenarios

  • When injected proximal to coils in

branches of the iliac, splenic, and renal arteries, GPX formed a cohesive embolus that did not travel distal to the coils (Fig. 3).

  • In

an acute procedure, GPX demonstrated deep penetration into the rete mirabile, resulting in rapid complete occlusion with no signs

  • f

crossing into venous circulation (Fig. 3).

  • GPX totally occluded model wide-

neck aneurysms at both acute and 1 month evaluations with no signs

  • f

catheter

  • r

balloon adhesion. Explanted tissue appeared grossly normal (Fig. 3).

  • When

used as a stand-alone embolic, GPX demonstrated good distal penetration, filling down to the arterioles, and generating a stable occlusion.

  • In the porcine kidney model, kidney lobes embolized

with GPX had less flow at the acute and long term follow-up than those performed with Embozene Microspheres (40 µm).

  • When used in tandem with coils, the cohesiveness of

GPX allows it to form a proximal, complete occlusion without distal migration in different vessel/flow situations.

  • GPX is a flow directed embolic agent that appears to

have utility in a variety of embolization scenarios.

Onyx, Squid, Phil, Easyx and others

slide-3
SLIDE 3

GPX

  • Polymeres à charge opposées + Tantalum
  • Retenus par une barrière d’ions monovalents
  • Diminution de la concentration

Post Injection (0.9% Saline) Coacervate (6-9% Saline) Figure 1: GPX solidifies after delivery in response to decreasing salt concentration.

slide-4
SLIDE 4

Initial angiogram 15 minutes post 14 days post GPX placement

slide-5
SLIDE 5

Initial angiogram Coil placement Minimal

  • cclusion

With GPX: total

  • cclusion

Necropsy minutes post-injection: GPX did not fragment and displayed distal penetration

Figure 3: Diverse uses of

  • GPX. Top: With coil. Right:

Acute necropsy. Bottom: Swine rete mirabile (left) and aneurysm model (right).

Initial angiogram GPX embolization No balloon adhesion after embolization of rabbit aneurysm

slide-6
SLIDE 6

Nouveaux liquides

Onyx, Squid, Phil, Easyx and others

  • GPX
  • Polymeres + solvant
  • Radio-opacité
  • Viscosité
  • Rupture technogique …
slide-7
SLIDE 7

The Fair-Embo Concept

Faisabilité in vivo de l’embolisation artérielle avec des fils de sutures

slide-8
SLIDE 8

Radiologie Interventionnell e

slide-9
SLIDE 9
slide-10
SLIDE 10

PRIX

slide-11
SLIDE 11

DISPONIBILITE DISTRIBUTION

slide-12
SLIDE 12
  • Promouvoir :
  • RI dans les pays émergents
  • Développement d’un agent d’embolisation :
  • Efficace
  • Disponible
  • Peu couteux

The Fair-Embo Concept

slide-13
SLIDE 13

13

Matériels & méthodes : Ex VIVO

slide-14
SLIDE 14

14

Matériels & méthodes : Ex VIVO

slide-15
SLIDE 15

Materiels & méthodes : In VIVO

  • AIGU : (n = 1)
  • Sécurité (hors cible)
  • Succès technique
  • mesenterique, splenique, pharyngée, rénale
  • Suture non-absorbable (SNA):
  • MersuturesT M 6, Ethicon (polyethylene terephthalate)
  • diamètre 0.8 and 0.899 mm, préparé en fragments de 1 à 3 cm
slide-16
SLIDE 16
  • Chronique (n = 3) :
  • efficacité et tolerance (moyen terme)
  • Artère polaire rénale inférieure :
  • Droite : SNA
  • Gauche : SA Vicryl, polyglactin 910: Ethicon.
  • Suivi 3 mois.
  • Suture taille 1
  • diametre USP
  • 0.4 / 0.5 mm, fragments de 1 cm (3 mg)

Materiels & méthodes : In VIVO

slide-17
SLIDE 17

Protocole

CT- Scanner Angiographie Histological study J-1 J0 M1 M3 X X X X X X X

Materiels & méthodes : In VIVO

slide-18
SLIDE 18
  • AIGU:
  • Securité
  • Succès technique

Résultats : In VIVO

slide-19
SLIDE 19
  • AIGU:
  • Polyethylene terephthalate
  • 6 USP (0.8–0.9 mm) 4 Fr (0.97 mm)
  • Variation possible 1 à 3 cm voir plus
  • Occlusion rapide avec 2 à 4 fragments (9.3 ± 3.4 cm).

Résultats : In VIVO

slide-20
SLIDE 20
  • CHRONIQUE:
  • Rein Dt: SNA, polyethylene terephthalate
  • 1 cm USP 1 : 21.3 ± 5.6 fragments (0.064 g ± 0.017, n = 3).
  • Rein Gch: SA, polyglactin 910
  • 1 cm USP 1 : 17.7 ± 4.6 fragments (0.053 g ± 0.014, n = 3).

Résultats : In VIVO

slide-21
SLIDE 21
  • Angiographie à 3 mois

SNA SA J0 M3 J0 M3

n°1 n°2 n°3

Résultats : In VIVO

slide-22
SLIDE 22
  • Scanner à 1 et 3 mois :
  • Pas de complications (abces, urinome).

Résultats : In VIVO

  • 3 mois,
  • Atrophie

polaire inférieure

slide-23
SLIDE 23
  • SNA
  • Matériel non fragmenté retrouvé dans tous les

reins droits, rien à gauche (SA) !

Résultats : In VIVO

slide-24
SLIDE 24
  • SA totalement résorbé à 3 mois
  • Pas d’infiltration perivasculaire.
  • no significant difference of tissue fibroplasia, edema, neovascularization,

hemorrhage, necrosis, or polymorph nuclear cells, lymphocytes, plasma cells, macrophages and giant cells observed in all the sections.

Résultats : In VIVO

slide-25
SLIDE 25

PUBLICATION CVIR April 2019

slide-26
SLIDE 26

DISCUSSION

slide-27
SLIDE 27

DISCUSSION

slide-28
SLIDE 28

DISCUSSION

  • Avantages
  • Low cost
  • Disponibilité universelle
  • Facile d’utilisation (taille, flushable)
  • Toxicité (implantation)
  • Désavantages
  • Linéaire (accrochage, torpille gélatine)
  • Non radio-opaque (particules et gelatine)
slide-29
SLIDE 29

DISCUSSION

Suture la plus absorbable du marché :

  • (Vicryl, polyglactin 910)
  • resorption rates of:
  • 25% at 14 days, 50% at 21 days, 75% at 30 days
  • 100% at 42 days (peut etre plus court en endovasculaire).

Suture la moins chère du marché :

  • MersuturesTM (polyethylene terephthalate)
  • non résorbable
  • Embolisation définitive

Considering tissue suturing and according manufacturer information

slide-30
SLIDE 30

DISCUSSION

  • Impact pour les patients ?
  • Hémorragie des premières 24 h après délivrance,

polytraumas … représente une mortalité trés élevée dans les pays émergents

  • FAIR-Embolisation :
  • Réalisé avec un ampli et du matériel très simple
  • Aiguille
  • Cathéter 4-5 Fr
slide-31
SLIDE 31

DISCUSSION

  • Agents d’embolisation:
  • Dispositifs médicaux implantables (DMIs) :
  • Circuit légal et pharmaceutique
  • Problématique :
  • Pas LOW COAST mais AVAILABLE
slide-32
SLIDE 32

FAIR-EMBO PROJECT

  • Particules non sphériques:
  • tumeurs Bénignes (fibromes Afrique) et Malignes
  • Embolisation blanche
slide-33
SLIDE 33

33

slide-34
SLIDE 34

FAIR-EMBO PROJECT

  • Taille des micro-particules :
  • Panel 8 personnes avec analyse microscopique
  • Rhéometrie :
  • Pr Gilles SOULEZ - CHUM
  • Granulométrie, dispersion … suspension (polyamide)
  • Effets tissulaires :
  • Année recherche : Dr M. Di Bisceglie
  • Sénégal : Dr A.N DIOP
slide-35
SLIDE 35
  • L. Findeiss

SIR

  • A. Gangi

CIRSE

  • A. Diop

Western Africa

  • Y. Arai

APSCVIR

  • F. Carnevale

SthA IR

  • C. Bigot

Ambassadeur de France

FONDATION : AMU (Amidex)

slide-36
SLIDE 36

36

slide-37
SLIDE 37
  • Effort international
  • Multiples leadership
  • Chaque projet  destination
  • Promouvoir : RI en général
  • Ex : Pr DIOP - Dakar
  • école de l’embolisation pour Afrique de l’Ouest
  • Data de la communauté FairEmbo
  • Crédits OMS
slide-38
SLIDE 38

38

slide-39
SLIDE 39

CONCLUSION

  • Embolization avec SA et SNA
  • Faisable
  • Sécuritaire
  • Efficace